openPR Logo
Press release

Huateng Pharma Supplies Canagliflozin Intermediates With Commercial Scale Production

Huateng Pharma Supplies Canagliflozin Intermediates With

Canagliflozin is a medication used to treat type 2 diabetes. It is a third-line medication to be tried after metformin, a first-line medication for type 2 diabetes. It is used together with exercise and diet. It is not recommended in type 1 diabetes.

Mechanism action of Canagliflozin

Canagliflozin is a sodium-glucose cotransporter (SGLT2) inhibitor. Glucose filtered in the renal tubular lumen is mainly reabsorbed by SGLT2 expressed in the proximal renal tubule. By inhibiting SGLT2, cagliegin reduces the renal reabsorption of filtered glucose, lowers renal glucose threshold (RTG) and increases urine glucose excretion, thus reducing blood glucose.

It is important to note that SGLT2 inhibitors are safe because their hypoglycemic effect is insulin-independent and fasting increases compensatory production of hepatic endogenous glucose.

What are the effects of Canagliflozin?

1. Lower blood sugar

As a new type of hypoglycemic drug, Canagliflozin has obvious advantages compared with other drugs. Traditional hypoglycemic drugs keep sugar in the human body, while this type of drug directly excretes sugar through the kidneys, and only when the blood sugar exceeds the kidneys. When the glucose threshold is reached, the hypoglycemic effect is exerted, and the hypoglycemic effect is not stimulated by insulin secretion, so it will not cause the risk of hypoglycemia, so as to achieve the good effect of fast and safe hypoglycemia.

2. Cardiovascular protection

Several studies have shown that SGLT2 inhibitors have cardioprotective effects and can be used in the treatment of heart failure, not only improving patient outcomes, but also reducing hospitalization and mortality, and for heart failure with or without diabetes. certain effect. In addition, it also has the effect of improving atherosclerosis, myocardial energy metabolism and anti-fibrosis.

3. Antihypertensive effect

Clinical data show that Canagliflozin can reduce systolic blood pressure to varying degrees, and the reduction is significantly dose-dependent. For example, in the clinical trial of canagliflozin, compared with the placebo group, the reduction in systolic blood pressure was between 2.6-5.7 mmHg at a dose of 100 mg, and at a dose of 300 mg, the reduction in systolic blood pressure reached 3.5-7.9 between mmHg.

On the one hand, its mechanism of action is to lower blood pressure through urinary sodium excretion, and on the other hand, it has a hypotensive effect by reducing inflammation and oxidative stress, improving vascular cell function and reducing arteriosclerosis. While exerting antihypertensive effect, it will not cause hyponatremia.

4. Weight loss

Canagliflozin reduce energy through the action of urine sugar, and at the same time induce the browning of white adipose tissue. Since there are two main types of fat in humans, namely white fat and brown fat, the former stores energy and the latter produces heat and consumes energy, so brown fat is increased. Quantity can increase energy consumption, improve metabolism, and achieve weight loss.

5. Decreased uric acid

Canagliflozin can lead to increased uric acid excretion, reducing uric acid in the body. However, compared with the classic uric acid-lowering drugs, its effect is relatively weak, so it is more promising to be used in patients with asymptomatic hyperuricemia or diabetes complicated with hyperuricemia.

6. Liver protection

SGLT2 inhibitors can protect the liver by altering the glucose-fatty acid cycle, increasing the utilization and oxidation of fatty acids in skeletal muscle, adipose tissue and the liver, thereby reducing the accumulation of fatty acids in the liver. Clinical data show that SGLT2 inhibitors can prevent and treat nonalcoholic fatty liver disease to a certain extent.

Huateng Pharma is a leading and professional manufacturer which can provide pharmaceutical intermediates, PEG derivatives, biochemical reagents, APIs, Vitamin D Derivatives and so on. After research and development, Huateng Pharma can provide the following four intermediates of Canagliflozin at present.

CAS NO.1132832-75-7
CAS NO.898566-17-1
CAS NO.1030825-20-7
CAS NO.58861-48-6

Hunan Huateng Pharmaceutical Co. Ltd.
Address: Lugu Business Plaza E1, Yuelu District, Changsha City, Hunan Province, China
Manufacturing Base: Tongguan Kiln, Wangcheng district, Changsha, Hunan, China
Zip code: 410205
Telephone: +86 731 89916275
Fax: +86 0731-82251112-818

Huateng Pharma is a leading and professional manufacturer which can provide pharmaceutical intermediates, PEG derivatives, biochemical reagents, APIs, Vitamin D Derivatives and so on. We have a 34,000 square meter manufacturing site with advanced design concept of intelligent manufacturing, which can realize the integration of the production process and accomplish the complete transformation of lab scale - pilot plant - large-scale commercial production, with an annual capacity of more than 1 billion RMB.

This release was published on openPR.

Permanent link to this press release:

Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Huateng Pharma Supplies Canagliflozin Intermediates With Commercial Scale Production here

News-ID: 2635597 • Views: 97

More Releases from Hunan Huateng Pharmaceutical Co. Ltd.

Huateng Pharma Develops Systemic Antiparasitic Agent Fluralaner
Fluralaner is a systemic insecticide and acaricide that can be administered orally or topically. Bravecto is the trade name. The U.S. Food and Drug Administration (FDA) approved it for flea treatment in dogs under the trade name Bravecto in May 2014 and for topical treatment in cats in November 2019. Fluralaner is a novel isooxazoline broad-spectrum insecticide that acts on γ-aminobutyric acid (GABA) receptors and has good activity against ticks, fleas,
Huateng Pharma Develops Intermediates of Carfilzomib For Multiple Myeloma
Carfilzomib, a proteasome inhibitor, is indicated for the treatment of patients with multiple myeloma. Multiple myeloma (multiple myeloma, MM) is a malignant tumor originating from the B cell lineage, characterized by the clonal proliferation of malignant plasma cells in the bone marrow microenvironment, causing fractures and bone marrow failure, and is the second most common blood system disease in the world Tumors cannot be cured by traditional chemotherapy regimens. Bortezomib is the
Huateng Pharma Develops Intermediates of Semaglutide For TD2
According to the latest IDF Diabetes map, the global prevalence of diabetes reached 10.5% in 2021, with 537 million adults living with diabetes. China has become a disaster zone for diabetes, with the largest number of adults with diabetes in the world. In the past 10 years (2011-2021), the number of people with diabetes in China increased from 90 million to 140 million, an increase of 56%. The total number
The Future of Treatment For Type 2 Diabetes
Although the treatment of type 2 diabetes (T2DM) has made impressive progress in the past few decades, researchers are constantly searching for new treatments. How to better control blood glucose and reduce diabetes-related complications has become a hot topic in the field of T2DM research. Previously, The Lancet Diabetes Endocrinology published an in-depth review detailing novel therapeutic targets for T2DM, mechanisms of drug action, and corresponding hypoglycemic efficacy. It involves innovation

All 5 Releases

More Releases for Canagliflozin

 Canagliflozin Drug Market 2022 Size, Growth Analysis Report, Forecast to 2028
The canagliflozin drug market is anticipated to grow at a significant CAGR during the forecast period (2022-2028). Canagliflozin drug is prescribed in the treatment of type 2 diabetes. It lowers the blood sugar level in the body. A high concentration of blood sugar in the body is seen in type 2 diabetes. In this condition, the body lacks the production of insulin or functions it smoothly. Canagliflozin drug comes under
Canagliflozin Hemihydrate Trends and Forecast Report 2022 | By Players, Types, A …
The QY Research released a latest market research report on the global and United States Canagliflozin Hemihydrate market, which is segmented by region (country), players, by Type and by Application. Players, stakeholders, and other participants in the global Canagliflozin Hemihydrate will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by region (country), by Type
Global Antidiabetic SGLT-2 Inhibitor Sales Market Size, Status Analysis, Growth …
The market for pharmaceutical industry growing with the expansion of this Industry Sector Worldwide. Market Research Hub (MRH) has added a new report titled “Global Antidiabetic SGLT-2 Inhibitor Sales Market Size, Status Analysis, Growth & Forecast during 2018-2025”which offer details about the current trends as well as scope for the near future. This research study also covers information about the production and market share based on different active regions. Furthermore,
Antidiabetic SGLT-2 Inhibitor Market Analysis- Size, Share, Growth, Industry Dem …
The Global Antidiabetic SGLT-2 Inhibitor Market Research Report 2017 renders deep perception of the key regional market status of the Antidiabetic SGLT-2 Inhibitor Industry on a global level that primarily aims the core regions which comprises of continents like Europe, North America, and Asia and the key countries such as United States, Germany, China and Japan. Request For Sample Of Antidiabetic SGLT-2 Inhibitor Market Research Report @ The report on “Global
Global Antidiabetic SGLT-2 Inhibitor Sales Industry Analysis, Growth, Demand, St …
Market Research Hub's report studies sales (consumption) of Global Antidiabetic SGLT-2 Inhibitor market, especially in United States, China, Europe and Japan, focuses on top players in these regions/countries, with sales, price, revenue and market share for each player in these regions, covering Anderson Hay & Grain Inc. Border Valley Sanofi Johnson & Johnson Bristol-Myers Squibb AstraZeneca Boehringer Ingelheim GlaxoSmithKline Pfizer Takeda Pharmaceuticals Eli Lilly Merck & Co. Novo Nordisk Request Free Sample Report@ Market Segment by Regions, this report splits Global into several key
Diabetes and obesity therapeutics market will more than double to $163.2 billion …
Report Title: Global Diabetes and Obesity Drugs Market to 2022 The global market for diabetes mellitus and obesity is set to rise from $70.8 billion in 2015 to $163.2 billion by 2022, at a strong compound annual growth rate of 12.7%. Callum Dew, Associate Analyst for GBI Research, explains: “Recent approvals and pipeline products that are expected to be key players during the forecast period include Tresiba (insulin degludec), Invokana (canagliflozin)